Gujarat Themis Biosyn Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 378.6 as of 06 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd is 0 as of March 2023 .The P/E Ratio of Sandu Pharmaceuticals Ltd is 33.3 as of March 2023 . The Market Cap of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sandu Pharmaceuticals Ltd is ₹ 50.43 crore as of March 2023 . The revenue of Gujarat Themis Biosyn Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 14.14 crore as compare to the Dec '24 revenue of ₹ 18.4 crore. This represent the decline of -23.15% The ebitda of Gujarat Themis Biosyn Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 0.52 crore as compare to the Dec '24 ebitda of ₹ 1.02 crore. This represent the decline of -49.02% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.33 crore over 4 quarters. This represents a CAGR of 94.12% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 49.86 % on March 2025 . This represents a CAGR of 6.54% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Limited (SPL) was established in 1987.
The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name 'SANDU' and is having a plant unit in Goa. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Sandu Pharmaceuticals Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,125 Cr while Market cap of Sandu Pharmaceuticals Ltd is 40 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Sandu Pharmaceuticals Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Sandu Pharmaceuticals Ltd?

As of May 6, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹378.6. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹41.9.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.